0M4 Stock Overview A clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Mersana Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Mersana Therapeutics Historical stock prices Current Share Price US$0.84 52 Week High US$5.34 52 Week Low US$0.84 Beta 1.42 1 Month Change -66.60% 3 Month Change -49.41% 1 Year Change -69.00% 3 Year Change -83.54% 5 Year Change -88.88% Change since IPO -92.97%
Recent News & Updates
Mersana Therapeutics, Inc. Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) Jan 10
Third quarter 2024 earnings released: US$0.094 loss per share (vs US$0.35 loss in 3Q 2023) Nov 15
New major risk - Revenue and earnings growth Nov 13
Mersana Therapeutics, Inc. Provides Business Update Nov 13
Mersana Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.47 loss in 2Q 2023) Aug 14 See more updates
Mersana Therapeutics, Inc. Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) Jan 10
Third quarter 2024 earnings released: US$0.094 loss per share (vs US$0.35 loss in 3Q 2023) Nov 15
New major risk - Revenue and earnings growth Nov 13
Mersana Therapeutics, Inc. Provides Business Update Nov 13
Mersana Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.47 loss in 2Q 2023) Aug 14
Mersana Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024 Aug 06
First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.52 loss in 1Q 2023) May 09
Mersana Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Mersana Therapeutics, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Full year 2023 earnings released: US$1.48 loss per share (vs US$2.18 loss in FY 2022) Feb 29 Mersana Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Feb 29
Mersana Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Mersana Therapeutics, Inc. Announces Business Updates Jan 05
Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.61 loss in 3Q 2022) Nov 09
New major risk - Revenue and earnings growth Nov 08 Mersana Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes
Second quarter 2023 earnings released: US$0.47 loss per share (vs US$0.55 loss in 2Q 2022) Aug 09
Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization Jul 28
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials Jun 16
Insufficient new directors May 23
Full year 2022 earnings released: US$2.18 loss per share (vs US$2.41 loss in FY 2021) Mar 01
Mersana Therapeutics, Inc. Initiates Expansion Portion of Upgrade-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer Feb 02
Mersana Therapeutics, Inc. Announces Initiation of Phase 1 Trial of XMT -2056 in Her2-Expressing Tumors Jan 26
Third quarter 2022 earnings released: US$0.61 loss per share (vs US$0.63 loss in 3Q 2021) Nov 08
Mersana Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Nov 01
Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer Oct 07
Mersana Therapeutics Inc. Announces Launch of Oncology Facets Oct 01
Mersana Therapeutics, Inc. Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers Aug 17
Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.59 loss in 2Q 2021) Aug 09
Mersana Therapeutics, Inc. Announces FDA Grant of Orphan Drug Designation to Xmt-2056 for the Treatment of Gastric Cancer May 20
First quarter 2022 earnings released: US$0.59 loss per share (vs US$0.50 loss in 1Q 2021) May 10
Mersana Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022 May 02
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting Apr 06
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 01
Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.33 loss in 3Q 2020) Nov 10
Chief Manufacturing Officer Michael Kaufman has left the company Sep 15
First half 2021 earnings released: US$1.09 loss per share (vs US$0.68 loss in 1H 2020) Aug 08
First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.35 loss in 1Q 2020) May 12
Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin (XMT-1536) in AACR Journal Molecular Cancer Therapeutics Mar 16
Mersana Therapeutics, Inc. Appoints Allene Diaz to Serve as A Class II Director Mar 12
Full year 2020 earnings released: US$1.43 loss per share (vs US$0.65 loss in FY 2019) Mar 01
Revenue misses expectations Mar 01
Mersana Therapeutics, Inc. Appoints Carla Poulson as Chief Human Resources Officer Jan 20
Mersana Therapeutics, Inc. Provides Update on Expansion Study Data for XMT-1536 Jan 06
New 90-day high: €21.60 Dec 23
Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer Dec 01
New 90-day high: €21.20 Nov 25
Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline Nov 12
Third quarter 2020 earnings released: US$0.33 loss per share Nov 10
Revenue misses expectations Nov 10
Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study Sep 18
New 90-day low - €14.20 Sep 05
Earnings released Aug 07
Mersana Therapeutics, Inc. to Report Q2, 2020 Results on Aug 07, 2020 Aug 01
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Microcap Value Index Jul 03 Shareholder Returns 0M4 DE Biotechs DE Market 7D -36.0% 6.5% 1.3% 1Y -69.0% -1.9% 9.0%
See full shareholder returns
Return vs Market: 0M4 underperformed the German Market which returned 10.1% over the past year.
Price Volatility Is 0M4's price volatile compared to industry and market? 0M4 volatility 0M4 Average Weekly Movement 18.3% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0M4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0M4's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Show more Mersana Therapeutics, Inc. Fundamentals Summary How do Mersana Therapeutics's earnings and revenue compare to its market cap? 0M4 fundamental statistics Market cap €156.75m Earnings (TTM ) -€72.84m Revenue (TTM ) €34.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0M4 income statement (TTM ) Revenue US$34.84m Cost of Revenue US$72.23m Gross Profit -US$37.39m Other Expenses US$37.23m Earnings -US$74.62m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.60 Gross Margin -107.33% Net Profit Margin -214.19% Debt/Equity Ratio 2,426.8%
How did 0M4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 06:08 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mersana Therapeutics, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Thomas Shrader BTIG Justin Zelin BTIG
Show 13 more analysts 
